June 6 (Reuters) - AbbVie Inc (NYSE:ABBV) ABBV.N :
* ABBVIE RECEIVES POSITIVE RECOMMENDATION FROM THE PAN-CANADIAN ONCOLOGY DRUG REVIEW EXPERT REVIEW COMMITTEE FOR THE COMBINATION VENCLEXTA® WITH RITUXIMAB AS A TREATMENT FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA